Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT07284459 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

324

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: PIPE-791 Dose A
DRUG: PIPE-791 Dose B
DRUG: Placebo

Sponsor

Contineum Therapeutics